Panel Discussion | ACS & AMI 2026 Contemporary Topics

Sunday, March 8, 2026

5:11 PM - 5:30 PM EST

Location: Lincoln

Moderator(s)

Ankur Kalra, MD

Division Chief of Cardiology
State University of New York (SUNY) Upstate Medical Center University, New York, United States

Disclosure(s): No financial relationships to disclose
Rony Lahoud, MD

Associate Professor
University of Vermont
S. Burlington, Vermont, United States

Disclosure(s): Abbott Vascular, Medtronic, Boston Scientific: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Ablative Solutions, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Edwards Lifesciences LLC: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
Sameer Mehta, MD

Chairman
Lumen Foundation
Miami, Florida, United States

Disclosure(s): No financial relationships to disclose

Panel Discussant(s)

Davide Capodanno, MD, PhD

Full Professor
Division of Cardiology, CAST, "Policlinico-Vittorio Emanuele", University of Catania
Catania, Sicilia, Italy

Disclosure(s): Novo Nordisk: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
C. Michael Gibson, MD

Professor of Medicine
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States

Disclosure(s): Amgen, Chiesi, Angel/Avertix Medical, Anthos Therapeutics, Janssen Pharmaceuticals, Johnson & Johnson Corporation, Bayer Corporation, Corsear, MashUp MD, Bioclinica, MD Magazine, Boehringer Ingelheim, Merck, Boston Clinical Research Institute, MjHeal: Consulting Fees (e.g., advisory boards) (Ongoing); HeartBeam, nference, Flow Therapy, Celecor, Fortress Biotech, TribeMD (Co-Founder), Generable and Lexaria: Stock Options [in privately held companies] (Ongoing); Johnson & Johnson Corporation, CSL Behring, SCAD Alliance, NACAM Trial (Sub-award - 5R01HL151996-05), and Janssen Pharmaceuticals.: Grant/Research Support (Ongoing); UpToDate in Cardiovascular Medicine: Royalties (Ongoing)
Krishnaraj S. Rathod, MBBS, BMedSci (Hons), MRCP (UK), PhD, FHEA, QDip, PGDip, MSc, FESC

Interventional Cardiology Consultant
Bart Heart Centre, St. Bartholomew's Hospital
London, England, United Kingdom

Disclosure(s): No financial relationships to disclose
Yasser Sammour, MD, MSc

Interventional Cardiology Fellow
Emory University School of Medicine

Disclosure(s): No financial relationships to disclose
Pieter C. Smits, PhD, FESC

Chief Medical Director
CERC (Cardiovascular European Research Center)
Rotterdam, Zuid-Holland, Netherlands

Disclosure(s): Abbott Vascular: Consulting Fees (e.g., advisory boards) (Terminated, October 1, 2025), Grant/Research Support (Terminated, October 1, 2025); CERC ( centre european of cardiovascular research): Employee (Ongoing), Stock-privately held company (Ongoing); MicroPort Medical: Consulting Fees (e.g., advisory boards) (Ongoing); SMT: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, October 1, 2025)
Ji Young Park, MD, PhD

Professor
Nowon Eulji Medical Center, Eulji University
Seoul, Seoul-t'ukpyolsi, Republic of Korea

Disclosure(s): No financial relationships to disclose

Disclosure(s):

Ankur Kalra, MD: No financial relationships to disclose

Rony Lahoud, MD: Abbott Vascular, Medtronic, Boston Scientific: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Ablative Solutions, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Edwards Lifesciences LLC: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

Sameer Mehta, MD: No financial relationships to disclose

Davide Capodanno, MD, PhD: Novo Nordisk: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

C. Michael Gibson, MD: Amgen, Chiesi, Angel/Avertix Medical, Anthos Therapeutics, Janssen Pharmaceuticals, Johnson & Johnson Corporation, Bayer Corporation, Corsear, MashUp MD, Bioclinica, MD Magazine, Boehringer Ingelheim, Merck, Boston Clinical Research Institute, MjHeal: Consulting Fees (e.g., advisory boards) (Ongoing); HeartBeam, nference, Flow Therapy, Celecor, Fortress Biotech, TribeMD (Co-Founder), Generable and Lexaria: Stock Options [in privately held companies] (Ongoing); Johnson & Johnson Corporation, CSL Behring, SCAD Alliance, NACAM Trial (Sub-award - 5R01HL151996-05), and Janssen Pharmaceuticals.: Grant/Research Support (Ongoing); UpToDate in Cardiovascular Medicine: Royalties (Ongoing)

Krishnaraj S. Rathod, MBBS, BMedSci (Hons), MRCP (UK), PhD, FHEA, QDip, PGDip, MSc, FESC: No financial relationships to disclose

Yasser Sammour, MD, MSc: No financial relationships to disclose

Pieter C. Smits, PhD, FESC: Abbott Vascular: Consulting Fees (e.g., advisory boards) (Terminated, October 1, 2025), Grant/Research Support (Terminated, October 1, 2025); CERC ( centre european of cardiovascular research): Employee (Ongoing), Stock-privately held company (Ongoing); MicroPort Medical: Consulting Fees (e.g., advisory boards) (Ongoing); SMT: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, October 1, 2025)

Ji Young Park, MD, PhD: No financial relationships to disclose